The Affordable Medicines Facility – malaria is an innovative financing mechanism designed to expand access to the most effective treatment for malaria, artemisinin-based combination therapies (ACTs).
The Affordable Medicines Facility – malaria is a new line of business hosted and managed by the Global Fund. Financial support for the initiative will come from UNITAID, the UK Department for International Development (DFID), and potentially other donors. The Roll Back Malaria Partnership will continue in its important role as a partner to the Affordable Medicines Facility – malaria.
The Affordable Medicines Facility – malaria aims to enable countries to increase the provision of affordable ACTs through the public, private and NGO sectors. This will save lives and reduce the use of less-effective treatments to which malaria parasites are becoming increasingly resistant. It will also reduce the use of artemisinin as a single treatment or monotherapy, thereby delaying the onset of resistance to that drug and preserving its effectiveness.
To achieve this aim, the Global Fund, as host and manager of the AMFm, has negotiated with drug manufacturers to reduce the price of ACTs, and to require that sales prices must be the same for both public and private sector first-line buyers. This is the first major achievement of the AMFm. Private importers now pay up to 80 percent less than they did in 2008-2009. The Global Fund pays most of this reduced price (a ‘buyer co-payment’) directly to manufacturers to further lower the cost to eligible first-line buyers of ACTs purchased from manufacturers. This means that first-line buyers only pay the remainder of the sales price for the ACTs. First-line buyers are expected to pass on the highest possible proportion of this price benefit so that patients are able to buy ACTs across the public, private, not-for-profit and for-profit sectors at prices that are less than those of oral artemisinin monotherapies and competitive with the prices of CQ and SP.
AMFm Phase 1 is being implemented through nine pilots in eight countries: Cambodia, Ghana, Kenya, Madagascar, Niger, Nigeria, Tanzania (including Zanzibar) and Uganda. Following the Global Fund Board’s decisions on successful applications to Phase 1 in November 2009, grant amendments or new grant agreements have been signed with most AMFm Phase 1 countries and implementation has started in several countries. The first co-paid ACTs were delivered to Ghana and Kenya in August 2010.”.
If you have any questions about Affordable Medicines Facility – malaria, please consult the Frequently Asked Questions or contact the Global Fund at the following address:
The AMFm was inspired by a landmark report, “Saving Lives, Buying Time”, published in 2004 by a Committee of the Institutes of Medicine (IOM) of the National Academy of Sciences, USA. Professor Kenneth Arrow, Nobel Laureate in economics, chaired the Committee. Under the umbrella of the Roll Back Malaria Partnership, and with financing from the Bill and Melinda Gates Foundation, the World Bank convened and managed an initiative that developed the principles of the IOM report into a policy that was adopted by major institutions in malaria control, and endorsed in November 2008 by the Board of the Global Fund. Many institutions, working groups and individuals contributed to the development of the Affordable Medicines Facility – malaria, including the RBM Task Force for the AMFm, the Ministry of Foreign Affairs of The Netherlands, UK-DFID, UNICEF, WHO, Ministers of Health and analysts from malaria-endemic countries, Resources For the Future, the William J. Clinton Foundation, scientists at think tanks, civil society groups, the private sector, academia, and others.
Affordable Medicines Facility - malaria
An innovative financing mechanism designed to expand access to the most effective treatment for malaria, artemisinin-based combination therapies (ACTs)
Contact | Legal | RSS | Sitemap
© 2013 The Global Fund to Fight AIDS, Tuberculosis and Malaria